Live Breaking News & Updates on Lipid Modifying Therapy Use

Stay updated with breaking news from Lipid modifying therapy use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly Leqvio, in addition to statin therapy, provides consistent low-density lipo. ....

United States , South Korea , Noord Holland , David Soergel , Novartis Leqvio , Sloan Simpson , Michael Meo Marlena Abdinoor , Coll Cardiol , Julie Masow , Los Angeles , Norman Lepor , Metabolic Drug Development , Exchange Commission , Public Health , Congress On , Novartis Pharmaceuticals Corporation , American Heart Association , European Union , National Cholesterol Education Program , European Medicines Agency , National Medical Products Administration , World Health Organization , Alnylam Pharmaceuticals , Vasc Health Risk Manag , Drug Administration , Impact Of Lipids On Cardiovascular Health ,

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, today announced completion of a $196M (‚¬160M) Series A funding round.
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor, is being developed for patients who are not well-controlled on statins.
Forbion, NAPs founding investor, was joined by Morningside Ventures and Ascendant BioCapital as co-lead investors in the Series A financing. Also participating in this funding round were Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dement ....

North Lanarkshire , United Kingdom , Noord Holland , Newamsterdam Pharma , Jason Dinges , Dezima Pharma , Gaurav Gupta , Michael Davidson , Peter Thiel , John Kastelein , Christopher Knospe , Dementia Fund , Population Health Partners , Mcdougall Communications , Kaiser Foundation Hospitals , Morningside Ventures , Ascendant Biocapital , Janus Henderson Investors , Amsterdam Pharma , Wide Cross Sectional Observational Study , Lipid Modifying Therapy Use , Primary Care , European Journal , Preventive Cardiology , Investor Inquiries , Dougall Communications ,